Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
Authors
Keywords
Type 2 diabetes, GLP-1 receptor agonist, Exenatide twice daily, Cardiovascular risk, High-sensitivity C-reactive protein
Journal
Cardiovascular Diabetology
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-09-03
DOI
10.1186/s12933-015-0279-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
- (2015) Lawrence Blonde et al. Cardiovascular Diabetology
- Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy
- (2015) Eusebio Chiefari et al. Diabetes Technology & Therapeutics
- Five-Year Efficacy and Safety Data of Exenatide Once Weekly
- (2015) Carol H. Wysham et al. MAYO CLINIC PROCEEDINGS
- Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
- (2014) Francisco Kerr Saraiva et al. Cardiovascular Diabetology
- Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients
- (2014) Chun-Jun Li et al. Cardiovascular Diabetology
- Sulfonylurea Use and Incident Cardiovascular Disease Among Patients With Type 2 Diabetes: Prospective Cohort Study Among Women
- (2014) Yanping Li et al. DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls
- (2014) C. A. Bannister et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities
- (2014) Asger Lund et al. European Journal of Internal Medicine
- Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients
- (2014) G. T. Russo et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
- (2013) Wendy L. Bennett et al. ANNALS OF INTERNAL MEDICINE
- Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals
- (2013) Alison R Meloni et al. Cardiovascular Diabetology
- Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter
- (2013) P. Valensi et al. DIABETOLOGIA
- Effect of lifestyle intervention on cardiometabolic risk factors: results of the POWER-UP trial
- (2013) M L Vetter et al. INTERNATIONAL JOURNAL OF OBESITY
- 2013 ESH/ESC Guidelines for the management of arterial hypertension
- (2013) Giuseppe Mancia et al. JOURNAL OF HYPERTENSION
- Investigation of the haemodynamic effects of exenatide in healthy male subjects
- (2012) Buddhike Mendis et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*
- (2012) S. Paul et al. DIABETES OBESITY & METABOLISM
- Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function
- (2012) T. Forst et al. DIABETIC MEDICINE
- Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
- (2012) Baptist Gallwitz et al. LANCET
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- Patterns of Weight Change Associated With Long-Term Weight Change and Cardiovascular Disease Risk Factors in the Look AHEAD Study
- (2012) Rebecca H. Neiberg et al. Obesity
- Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
- (2011) Robert Ratner et al. Cardiovascular Diabetology
- Clinical Use of Liraglutide in Type 2 Diabetes and its Effects on Cardiovascular Risk Factors
- (2011) Ajay Varanasi et al. Endocrine Practice
- Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition
- (2010) M. C. Bunck et al. DIABETES CARE
- Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database
- (2010) J. H. Best et al. DIABETES CARE
- Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
- (2010) D. R. Matthews et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
- (2010) A. Garber et al. DIABETES OBESITY & METABOLISM
- Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes
- (2008) Katerina Papathanassiou et al. ATHEROSCLEROSIS
- Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride
- (2008) Cindy J Rubin et al. Diabetes & Vascular Disease Research
- Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
- (2008) Alan Garber et al. LANCET
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started